Natera, Inc. is a clinical genetic testing company based in Austin, Texas that specializes in non-invasive, cell-free DNA (cfDNA) testing technology, with a focus on women's health, cancer, and organ health. Natera's proprietary technology combines novel molecular biology techniques with a suite of bioinformatics software that allows detection down to a single molecule in a tube of blood. Natera operates CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, California and Austin, Texas.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| NTRA | Natera, Inc. | 2026-04-02 18:58:03 | 212 | 4.02 | 1.93 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NTRA | 0001604821 | Natera, Inc. | US6323071042 | 529900CQ3OZ0A0VYVU59 | 010894487 | Nasdaq | 8071 | Services-Medical Laboratories | 1231 | DE | 13011 MCCALLEN PASS | AUSTIN | TX | 78753 | UNITED STATES | US | 650-249-9090 | 13011 MCCALLEN PASS, AUSTIN, TX, 78753 | 13011 MCCALLEN PASS, AUSTIN, TX, 78753 | Natera, Inc. | Genetic testing | 2004 | Steve Chapman | 3,018 | https://natera.com | 21,830,000,000 | 139,693,000 | 141,731,250 | Natera, Inc. is a clinical genetic testing company based in Austin, Texas that specializes in non-invasive, cell-free DNA (cfDNA) testing technology, with a focus on women's health, cancer, and organ health. Natera's proprietary technology combines novel molecular biology techniques with a suite of bioinformatics software that allows detection down to a single molecule in a tube of blood. Natera operates CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, California and Austin, Texas. | 2026-04-02 15:33:37 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 21,830,000,000 | 8,680,000,000 | 66.0076 | 141,731,250 | 6,545,066 | 4.8415 |
| 2024 | 13,150,000,000 | 7,890,000,000 | 150 | 135,186,184 | 14,428,307 | 11.9481 |
| 2023 | 5,260,000,000 | 2,690,000,000 | 104.6693 | 120,757,877 | 7,472,202 | 6.5959 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Solomon Moshkevich | President | 2024 | 490,032 | — | 4,103,350 | 285,574 | 9,900 | 4,888,856 |
| Matthew Rabinowitz | Executive Chairman | 2024 | 401,484 | — | 9,027,579 | 405,066 | 0 | 9,834,129 |
| Steven Chapman | Chief Financial Officer, President, Chief Executive Officer | 2024 | 799,948 | — | 11,284,474 | 938,352 | 9,900 | 13,032,674 |
| John Fesko | Chief Business Officer, President | 2024 | 490,032 | — | 4,103,350 | 285,574 | 9,900 | 4,888,856 |
| Daniel Rabinowitz | Chief Legal Officer | 2023 | 407,594 | — | 2,715,379 | 193,112 | 9,900 | 3,325,985 |
| Fiscal Year | Employee Count |
|---|---|
| 2020 | 1,815 |
| 2019 | 1,039 |
| 2018 | 975 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 2,306,113,000 | 1,696,911,000 | 1,082,571,000 |
| Cost Of Revenue | 810,627,000 | 672,304,000 | 588,564,000 |
| Gross Profit | 1,493,180,000 | 1,023,158,000 | — |
| Research And Development Expenses | 624,110,000 | 404,138,000 | 320,678,000 |
| General And Administrative Expenses | 1,177,261,000 | 841,314,000 | 618,307,000 |
| Operating Expenses | 2,616,024,000 | 1,919,205,000 | 1,528,816,000 |
| Operating Income | -309,911,000 | -222,294,000 | -446,245,000 |
| Net Income | -208,160,000 | -190,426,000 | -434,801,000 |
| Earnings Per Share Basic | -1.52 | -1.53 | -3.78 |
| Earnings Per Share Diluted | -1.52 | -1.53 | -3.78 |
| Weighted Average Shares Outstanding Basic | 136,721,000 | 124,718,000 | 114,997,000 |
| Weighted Average Shares Outstanding Diluted | 136,721,000 | 124,718,000 | 114,997,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 1,076,140,000 | 945,587,000 | 642,095,000 |
| Marketable Securities Current | — | 22,689,000 | 236,882,000 |
| Accounts Receivable | 296,528,000 | 314,165,000 | 278,289,000 |
| Inventories | 68,443,000 | 44,744,000 | 40,759,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 1,496,939,000 | 1,375,820,000 | 1,258,549,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 241,184,000 | 162,046,000 | 111,210,000 |
| Other Assets Non Current | 36,897,000 | 36,720,000 | 15,403,000 |
| Total Assets Non Current | 901,405,000 | 284,915,000 | 183,150,000 |
| Total Assets | 2,398,344,000 | 1,660,735,000 | 1,441,699,000 |
| Accounts Payable | 33,156,000 | 34,922,000 | 14,998,000 |
| Deferred Revenue | 24,907,000 | 19,754,000 | 16,612,000 |
| Short Term Debt | 80,323,000 | 80,362,000 | 80,402,000 |
| Other Liabilities Current | 188,659,000 | 146,893,000 | 149,405,000 |
| Total Liabilities Current | 441,228,000 | 344,045,000 | 307,274,000 |
| Long Term Debt | — | — | 282,945,000 |
| Other Liabilities Non Current | 11,687,000 | — | — |
| Total Liabilities Non Current | 244,703,000 | 121,270,000 | 369,098,000 |
| Total Liabilities | 685,931,000 | 465,315,000 | 676,372,000 |
| Common Stock | 14,000 | 12,000 | 11,000 |
| Retained Earnings | -2,776,022,000 | -2,567,862,000 | -2,377,436,000 |
| Accumulated Other Comprehensive Income | -258,000 | -344,000 | -3,085,000 |
| Total Shareholders Equity | 1,712,413,000 | 1,195,420,000 | 765,327,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 41,764,000 | 30,968,000 | 24,097,000 |
| Share Based Compensation Expense | 354,404,000 | 274,428,000 | 191,808,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | -20,752,000 | 35,876,000 | 33,904,000 |
| Change In Inventories | 20,871,000 | 3,985,000 | 5,353,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 753,000 | 13,210,000 | -15,458,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | 215,301,000 | 135,664,000 | -246,955,000 |
| Purchases Of Marketable Securities | — | 122,010,000 | 98,303,000 |
| Sales Of Marketable Securities | 23,000,000 | 24,822,000 | 306,000,000 |
| Acquisition Of Property Plant And Equipment | 106,188,000 | 66,423,000 | 39,199,000 |
| Acquisition Of Business | 16,021,000 | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -132,209,000 | 137,624,000 | 168,498,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 25,037,000 | — | — |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 47,461,000 | 30,204,000 | 254,461,000 |
| Change In Cash | 130,553,000 | 303,492,000 | 176,004,000 |
| Cash At End Of Period | 1,076,140,000 | 945,587,000 | 642,095,000 |
| Income Taxes Paid | 499,000 | 1,307,000 | 295,000 |
| Interest Paid | 4,069,000 | 7,897,000 | 11,346,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -1.52 | -1.53 | -3.78 |
| Price To Earnings Ratio | -150.7171 | -103.4641 | -16.5714 |
| Earnings Growth Rate | -0.6536 | -59.5238 | -32.1364 |
| Price Earnings To Growth Ratio | 230.5972 | 1.7382 | 0.5157 |
| Book Value Per Share | 12.5249 | 9.585 | 6.6552 |
| Price To Book Ratio | 18.2908 | 16.5154 | 9.4122 |
| Ebitda | -161,828,000 | -147,466,000 | -397,771,000 |
| Enterprise Value | — | — | 6,924,664,080 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | — | 0.4748 |
| Capital Expenditures | 120,902,000 | 81,804,000 | 42,854,000 |
| Free Cash Flow | 94,399,000 | 53,860,000 | -289,809,000 |
| Return On Equity | -0.1216 | -0.1593 | -0.5681 |
| One Year Beta | 1.1853 | 1.5412 | 1.1247 |
| Three Year Beta | 1.2472 | 1.5276 | 1.5861 |
| Five Year Beta | 1.4783 | 1.3693 | 1.3865 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Brophy Michael Burkes | Chief Financial Officer | 2029-06-23 | 12,500 | D | 37,500 |
| Brophy Michael Burkes | Chief Financial Officer | 2029-06-08 | 25,000 | D | 50,000 |
| RABINOWITZ DANIEL | SEC. AND CHIEF LEGAL OFFICER | 2026-04-01 | 1,909 | D | 224,885 |
| Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS | 2026-04-01 | 1,048 | D | 149,834 |
| Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS | 2026-04-01 | 1,000 | D | 148,834 |
| Name Of Reporting Person | Type Of Reporting Person | Report Date | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| William F Hagerty, IV | Senator | 2021-05-04 | Sale (Partial) | 2021-04-20 | Self | $1,001 - $15,000 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Josh Gottheimer | 2025-10-15 | NJ05 | Purchase | 2025-09-22 | Joint | $1,001 - $15,000 |
| Josh Gottheimer | 2025-09-05 | NJ05 | Purchase | 2025-08-22 | Joint | $1,001 - $15,000 |
| Josh Gottheimer | 2025-08-11 | NJ05 | Sale (Partial) | 2025-07-22 | Joint | $1,001 - $15,000 |
| Josh Gottheimer | 2024-12-05 | NJ05 | Purchase | 2024-11-20 | Joint | $1,001 - $15,000 |
| Daniel Goldman | 2023-05-19 | NY10 | Sale (Partial) | 2023-04-10 | — | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Investors Research Corp | 2026-03-31 | 1,800 | 9 | 200 |
| Hilltop National Bank | 2026-03-31 | 74,596 | 373 | 199.9893 |
| Aspect Partners, LLC | 2026-03-31 | 2,400 | 12 | 200 |
| GOLDMAN SACHS GROUP INC | 2025-12-31 | 9,163,600 | 40,000 | 229.09 |
| GOLDMAN SACHS GROUP INC | 2025-12-31 | 164,207,359 | 716,781 | 229.09 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| J.P. Morgan Exchange-Traded Fund Trust | 2026-01-31 | JPMorgan BetaBuilders U.S. Mid Cap Equity ETF | BBMC | 53,734 | 12,420,076.76 | 0.6394 |
| JPMorgan Trust I | 2026-01-31 | Class R3 | GAOTX | 7,677 | 1,774,461.78 | 0.0616 |
| JPMorgan Trust I | 2026-01-31 | Class R4 | GAOFX | 7,677 | 1,774,461.78 | 0.0616 |
| JPMorgan Trust I | 2026-01-31 | Class R5 | GAORX | 7,677 | 1,774,461.78 | 0.0616 |
| JPMorgan Trust I | 2026-01-31 | Class R6 | GAOZX | 7,677 | 1,774,461.78 | 0.0616 |